8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Oct 29, 2007)

Filed October 29, 2007For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated filed an 8-K report on October 29, 2007, to disclose its financial results for the quarter ended September 30, 2007. The report primarily incorporates by reference a press release issued on the same date, which details the company's financial performance and operational updates. Investors should pay close attention to the "Telaprevir Development Program," "Pipeline of Novel Drug Candidates," and "Special Note Regarding Forward-Looking Statements" sections of the press release, as this information is specifically designated as 'filed' and will be incorporated into future SEC filings.

Key Highlights

  • 1Vertex Pharmaceuticals announced its financial results for the third quarter of 2007 via an 8-K filing.
  • 2The report incorporates by reference a press release dated October 29, 2007, containing the detailed financial results.
  • 3Specific sections of the press release, including updates on the Telaprevir Development Program and the pipeline of novel drug candidates, are deemed "filed" and will be incorporated into other SEC filings.
  • 4This filing serves as an official notification of Vertex's Q3 2007 financial and operational status.
  • 5Investors are directed to the referenced press release for comprehensive details on performance and future outlook.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially report Vertex Pharmaceuticals' consolidated financial results for the third quarter ended September 30, 2007. It incorporates by reference a press release issued on October 29, 2007, which contains these financial results and other operational updates.

The sections of the press release that are deemed "filed" and therefore carry specific regulatory weight are the "Telaprevir Development Program," "Pipeline of Novel Drug Candidates," and "Special Note Regarding Forward-Looking Statements." Investors should review these specific areas for detailed information.

The detailed financial results and operational information are contained within the press release dated October 29, 2007, which is attached as Exhibit 99.1 to this 8-K filing and is incorporated by reference.